R&D

    Functional Probiotics

    Functional Probiotic Pipeline - Body Fat Reduction

    Pipeline
    Function
    Research
    Preclinical
    Human study
    Commercialization
    LABHEALTH-002
    Body Fat Reduction
    Obesity, whose global prevalence continues to rise, is defined by excessive accumulation of body fat resulting from an imbalance between energy intake and energy expenditure.
    It is closely associated with an increased risk of chronic conditions such as insulin resistance, diabetes, hypertension, and dyslipidemia.
    Therefore, reducing body fat is considered an important factor in maintaining and improving overall health.
    ATG-K2 demonstrated significant effects on body weight reduction, suppression of fat accumulation, and decreased adipocyte size in adipocyte models and high-fat diet–induced obese animal models. In adipose tissue, ATG-K2 reduced the expression of genes related to lipogenesis while increasing the expression of genes involved in fatty acid oxidation.
    In diet-induced obesity models, ATG-K2 also modulated the gut microbiota in ways associated with body fat reduction and increased levels of short-chain fatty acids.
    In human studies, ATG-K2 showed reductions in body fat mass and body fat percentage.
    Based on validated efficacy in both animal and human studies, ATG-K2 received product-specific functional approval from Korea’s Ministry of Food and Drug Safety as an individually approved functional ingredient for body fat reduction.